A CRISPR-Cas9 repressor for epigenetic silencing of KRAS
- 14 November 2020
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 164, 105304
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
This publication has 43 references indexed in Scilit:
- Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene ExpressionCell, 2013
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature, 2012
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activityProceedings of the National Academy of Sciences, 2012
- RAS oncogenes: weaving a tumorigenic webNature Reviews Cancer, 2011
- Functional Specificity of Ras Isoforms: So Similar but So DifferentGenes & Cancer, 2011
- KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patientsBritish Journal of Cancer, 2011
- Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted TherapyMolecular Cancer Therapeutics, 2011
- Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?Nature Reviews Cancer, 2010
- Genetic analysis of Ras signalling pathways in cell proliferation, migration and survivalThe EMBO Journal, 2010